

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**CSPC PHARMACEUTICAL GROUP LIMITED**  
**石藥集團有限公司**  
*(Incorporated in Hong Kong with limited liability)*  
**(Stock Code: 1093)**

**VOLUNTARY ANNOUNCEMENT**

**BIVALENT HPV mRNA THERAPEUTIC VACCINE (SYS6026)  
OBTAINS CLINICAL TRIAL APPROVAL**

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that SYS6026, a therapeutic bivalent messenger RNA (mRNA) vaccine against relevant precancerous lesions caused by human papillomavirus (HPV) type 16 or 18 (the “**Product**”) developed by the Group, has obtained approval granted by the National Medical Products Administration (NMPA) of the People’s Republic of China to conduct clinical trials in China.

The Product is the first therapeutic vaccine independently developed by the Group based on its mRNA platform, consisting of mRNA molecules combined with a lipid nanoparticle (LNP) delivery system. The Product expresses the mRNA-encoded E6 and E7 antigens of HPV type 16 or 18, generating antigen-specific T cells that could eliminate HPV-infected cells and inhibit tumorigenesis. Currently, clinical treatments primarily rely on surgery, which have drawbacks of severe patient harm and relapse tendency. As a highly effective non-surgical treatment option, the Product is expected to address significant clinical needs within this field, providing a promising clinical development value. Until now, there is no HPV therapeutic vaccine available on the market worldwide.

The indication for this clinical trial approval is the treatment of high-grade squamous intraepithelial lesion (HSIL) associated with HPV type 16 or 18.

By Order of the Board  
**CSPC Pharmaceutical Group Limited**  
**CAI Dongchen**  
*Chairman*

Hong Kong, 12 November 2024

*As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. JIANG Hao, Dr. YAO Bing and Mr. CAI Xin as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.*